{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-034928","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.319147+00:00","generated_at":"2026-05-15T08:52:18.266884+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dogwood provides HALT-CINP trial update; $12.5M raised, SP16 IND filed","bullets":["145 patients recruited in Halneuron Phase 2b HALT-CINP study; final data expected fall 2026.","Raised $12.5M in Q1 2026; combined with year-end cash extends runway through data release.","Filed IND for SP16 IV (chemo-induced neuropathy); Phase 1b fully funded by NCI grant.","Advanced synthetic Halneuron formulation for Phase 3; aims to cut costs and boost yields."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-034928","json":"https://secwatch.observer/filing/0001104659-26-034928.json","markdown":"https://secwatch.observer/filing/0001104659-26-034928.md","text":"https://secwatch.observer/filing/0001104659-26-034928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926034928/0001104659-26-034928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000110465926034928/dwtx-20260326x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:52:18.266884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}